Hyloris Pharmaceuticals Sa · EURONEXT:HYL
Hyloris Pharmaceuticals Sa — H1 2026 Earnings Presentation
43 slides from Hyloris Pharmaceuticals Sa's earnings presentation, Sep 24, 2026
Slide 1: Where others stop, we start and add value
Where others stop, we start and add value Reinventing Existing Medicines H1 2026 Results – Company Update 24 September 2026 Nice to meet you!
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, “presentation” means this document, oral presenta
Slide 3: Pharma needs faster & more affordable innovation
Pharma needs faster & more affordable innovation The traditional way thousands only a of drug candidates are fraction in the pipeline make it to market worldwide Slow Expensive Risky
Slide 4: Our Mission
Our Mission We add value through Reinventing Existing Medications for unmet patient needs worldwide
Slide 5: We think different by unlocking the hidden potential of existing medicines
We think different by unlocking the hidden potential of existing medicines Agile Affordable Efficient
Slide 6: Reinvent existing & Invent new medicines
Reinvent existing & Invent new medicines REFORMULATING REPURPOSING NCE Improve DOSAGE FORM and/or change Repurpose existing medicine for a ROUTE of administration of existing NEW therapeutic INDICATION (use) medicines New Chemical Entity Target to be MORE EFFECTIVE – MORE NEW PRODUCT – NEW FIELD usi
Slide 7: Reinvent existing & Invent new medicines
Reinvent existing & Invent new medicines REFORMULATING REPURPOSING NCE Facilitating A catalyst for co – development & growth with Third Parties
Slide 8: We always improve therapy outcomes & provide benefits
We always improve therapy outcomes & provide benefits for: Patients Physicians Payers
Slide 9: Driving faster innovation
Our Value Proposition: Driving faster innovation Reducing Time-to-Market, Cost & Clinical Burden average Traditional model for NCE’s & Biologics 15years up to Approved molecules Hyloris - model 7 years Reduction time (pre)clinical development Needs of Stakeholders taken into account Leverage public
Slide 10: FDA's 505(b)(2) pathway (or equivalent) as the engine
FDA’s 505(b)(2) pathway (or equivalent) as the engine Added value to healthcare system Addressing clear unmet needs Technical feasibility Clear scientific & medical rationale Fast market adoption Approved, well-known molecules ≤ 7 years to market Maximized ROI Defined regulatory pathway Large potent
Slide 11: A strong chain for shared success
A strong chain for shared success Approval to R&D & CMC pipeline Own Ideas Tech transfer to CDMO (puring process) Scientific Clinical R&D Academic Collaboration Regulatory Industry Collaboration Terms with collaboration TIMELINE Agreed value Scientific Revenu from global sharing with Partnerships Fi
Slide 12: A broad, high-value development portfolio driving sustainable growth
A broad, high – value development portfolio driving sustainable growth Commercial Partnerships (Products Launched) Maxigesic IV (value added / non-opioid analgesic) 30+ products 4 Sotalol IV Podofilox Gel (value added / cardiovascular) (high barrier generic / infectious diseases ) Tranexamic Acid IV
Slide 13: Our Product Portfolio: Strategic Focus Groups for Growth
Our Product Portfolio (as publicly announced) 3 Strategic Focus Groups for Growth
Slide 14: Our Product Portfolio: Strategic Focus Groups for Growth
Our Product Portfolio (as publicly announced) 3 Strategic Focus Groups for Growth MAVERICKS CORE DRIVERS PROMISING SEEDS A high-potential product backed A catalyst product building a An early-stage product pending with clinical evidence and strong recurring revenue base at clinical validation: signi
Slide 15: Our Product Portfolio (update): Strategic Focus Groups for Growth
Our Product Portfolio (update of those publicly announced) Product Fiches shared separately on website 3 Strategic Focus Groups for Growth MAVERICKS CORE DRIVERS PROMISING SEEDS HY-094 (Iron Deficiency Anemia) Maxigesic® IV HY-083 (Idiopathic Rhinitis) Milrinone ER Sotalol IV HY-095 (Equine Gastric
Slide 16: Key Products Funnel
Key Products Funnel
Slide 17: Broad, innovative cardiovascular portfolio
Broad, innovative cardiovascular portfolio Clinical Regulatory Filing and Target Product Route/Form Indication Formulation Development approval Market UP TO 7 YEARS Sotalol IV IV Atrial Fibrillation Partnered in the U.S. with AltaThera U.S. Aspirin IV IV Acute Coronary Syndrome WW Milrinone ER Oral
Slide 18: Other value-added portfolio
Other value-added portfolio Clinical Regulatory Filing and Target Product Route/Form Indication Formulation Development approval Market UP TO 7 YEARS Maxigesic® IV IV Post-operative pain Co-development with AFT Pharmaceuticals WW Podofilox Gel Topical Ext. genital/perianal warts Partnered in the U.S
Slide 19: Other value-added portfolio, cont'd
Other value-added portfolio, cont’d Clinical Regulatory Filing and Target Product Route/Form Indication Formulation Development approval Market UP TO 7 YEARS Injection Equine Gastric Ulcer Syndrome HY-095 (PPI) LAI WW Pantoprazole RTU Injection GERD and EE WW WW ex. U.S. Ondansetron ER Tablet Nausea
Slide 20: What sets us apart: Product Selection – ROI – Risk Profile
What sets us apart: Product Selection – ROI – Risk Profile Center of Excellence ▪ CMO search – efficiency for R&D and Regulatory ▪ Cost development ▪ Impressive KOL network Worldwide ▪ Worldwide partner/distribution ▪ Strategic Insights to indentify unmet medical needs network ▪ Patient-centric appr
Slide 21: Our 5 Strategic Pillars Of Excellence
Our 5 Strategic Portfolio Focus & Value Regulatory & Development Pillars Of Prioritization Excellence Excellence Concentrate capital and management attention on assets with the highest Drive efficient development pathways through strong formulation, CMC, clinical, probability of regulatory, commerci
Slide 22: Product Portfolio Fiches
Product Portfolio Fiches
Slide 23: HY-094 Ferric for injection
HY-094 Ferric for injection Indication: Iron Deficiency Anemia (IDA) Global Intravenous Iron Drugs Market Size 2023 to 2034 (USD Billion) 9 • Innovative NCE injectable iron therapy designed to overcome limitations of 8 current treatments for better convenience and tolerability 7 • Targeting global i
Slide 24: Alenura
Alenura Indication: Interstitial Cystitis/Bladder Pain Syndrome • Defect in inner lining of the bladder = chronic, recurring discomfort & pain Proven pain reduction in 2 • Alenura 15mL prefilled syringe with a dual mode of action: controlled Ph2 trials • Alkalinised lidocaine: penetrates bladder wal
Slide 25: HY-083 Idiopathic Rhinitis
HY-083 Indication: Idiopathic Rhinitis - chronic rhinitis without a known cause • Symptoms: Runny nose, stuffy nose, sneezing fits without a medical diagnosis (allergies, infection, inflammation, …) • Impacting quality of life daily (sleep patterns, drowsiness, irritability, poor concentration) • Mo
Slide 26: Global By Design: Our diversification Solutions & Markets
Global By Design: Our diversification Solutions & Markets
Slide 27: Products launched today
Products launched today Number of Products 3 North America Europe ◉ Cardiovascular ◉ Non-opioid analgesic ◉ Non-opioid analgesic 1 ◉ Anti-infectious APAC ◉ Non-opioid analgesic Africa ◉ Non-opioid analgesic 26/3/2026 – PR/Annual Results 2025 Powered by Bing © Australian Bureau of Statistics, GeoName
Slide 28: Expected product launches in coming years
Expected product launches in coming 3 years Europe Number of Products 7 ◉ Non-opioid analgesic North America ◉ Anti-infectious ◉ Cardiovascular ◉ Electrolyte and mineral ◉ Non-opioid analgesic 1 ◉ Bleeding ◉ Anti-infectious ◉ Dentistry APAC ◉ Mental- and behaviour ◉ Non-opioid analgesic ◉ Bleeding ◉
Slide 29: Patents granted today
Patents granted today Europe Patent North America ◉ Cardiovascular CIS 43 ◉ Cardiovascular ◉ Non-opioid analgesic ◉ Non-opioid analgesic ◉ Non-opioid analgesic ◉ Anti-infectious ◉ Anti-infectious ◉ Dentistry 0 ◉ Dentistry ◉ Urology ◉ Bleeding MENA ◉ Mental- and behaviour ◉ Oncology ◉ Non-opioid anal
Slide 30: Patents granted + patent applications
Patents granted + patent applications* (and continuous expansion) Patent+Application Europe 60 North America ◉ Cardiovascular CIS ◉ Cardiovascular ◉ Non-opioid analgesic ◉ Non-opioid analgesic ◉ Non-opioid analgesic ◉ Anti-infectious 1 ◉ Anti-infectious ◉ Dentistry ◉ Dentistry ◉ Urology ◉ Mental- an
Slide 31: Our Strategy
Our Strategy Multiple shots on goal Lower risk as we start 30+ from Innovative, Potential Multiple existing drugs value-added drug game changer, near term filings candidates ** geared for growth ≤ €7 million average cost to market* 3 products commmercialised Ambition to become the ≤ 7 years to marke
Slide 32: Symphonies sound monumental but we behave like a jazz band
Symphonies sound monumental but we behave like a jazz band: agile in every note, bold in every move
Slide 33: Where others stop, we go that extra mile
Where others stop, we go that extra mile. To cover unmet pharma needs. With compliance as our backbone, we give existing medicines a second life through patient-centric, advanced innovation. We do so together with our partner network. Aiming for trustworthy collaboration and responsible growth.
Slide 34: Highlights 2025
Highlights 2025
Slide 35: H1 2026: Advances Product Portfolio
H1 2026: Advances Product Portfolio With sharper focus Taking our products Pantoprazole IV RTU · Orion: EU, UK, CH, NO 3 NEW worldwide Maxigesic® IV · AFT: China PARTNERSHIPS Maxigesic® IV · Mikasa Seiyaku: Japan 2 REGULATORY Atomoxetine oral liquid · US approval request (NDA) filed with the FDA by
Slide 36: Financial Highlights HY 2026
Financial Highlights HY 2026 Operating Income Revenue increased 56% to €4.7 million, mainly driven by higher milestone income, including the Atomoxetine Oral Liquid regulatory (in € thousand) HY 2026 HY 2025 % change milestone and the Pantoprazole IV upfront. Including other operating income, operat
Slide 37: 2026: Milestones For The Year
2026: Milestones For The Year Key clinical, regulatory and commercial milestones CLINICAL REGULATORY COMMERCIAL Clinical trial starts Submissions Launch / deals Phase 1: Arbor-101, Pantoprazole IV, PTX-252 Dofetilide IV Tranexamic acid RTU launch Phase 2: Miconazole-DB in Bacterial Vaginosis Phospha
Slide 38: The Hyloris Share
The Hyloris Share 2026 Stijn Van Rompay 28% Thomas Jacobsen 43% Scorpiaux BV Nick Reunbrouck Pieter Van Rompay 12% Other Holders 3% 6% 8% Total number of outstanding voting rights (denominator) 28,000,374 For founders: Based on transparency notifications and latest denominator; Total number of secur
Slide 39: Hyloris at a glance
Hyloris at a glance Specialty High Yield Founded Pharma Company Low Risk 2012 Listed 2020 Broad HQ Quoted on pipeline Liège Euronext (Belgium) Brussels 30+ products HYL People Strong network 54 30 men & knowhow 24 women 12 countries 13 nationalities 4 continents
Slide 40: Our Core Values
Our Core Values Entrepreneurship Professional Excellence Passion & Integrity & Drive Accountability
Slide 41: The team behind the science & route to market
The team behind the science & route to market Stijn Van Rompay Thomas Jacobsen Dietmar Aichorn Christophe Maréchal Ann De Jaeger Co-CEO & Founder Co-CEO, CBDO & Founder COO CFO CLO >20 years of experience in leadership >20 years of experience in pharma. >20 years of experience in various >25 years o
Slide 42: Our People, Our Strength
Our People Our Strength
Slide 43: Value Starts Here
Value Starts Here Hyloris Pharmaceuticals SA - 2026 HQ: Boulevard Patience Et Beaujonc N°3/1 4000 Liège, Belgium +32(0)4 346 02 07 contact@hyloris.com investorrelations@hyloris.com
Hyloris Pharmaceuticals — H1 2026 Earnings Presentation on 6ix